Biomarkers and peak oxygen uptake in patients with chronic lung disease

Respiration

Volumn 80, Issue 6, 2010, Pages 543-552

  Maeder, Micha T ^a,b   Brutsche, Martin H ^c   Arenja, Nisha ^d   Socrates, Thenral ^d   Reiter, Miriam ^d   Meissner, Julia ^d   Staub, Daniel ^d   Morgenthaler, Nils G ^e   Bergmann, Andreas ^e   Mueller, Christian ^d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b Division of Cardiology   (Switzerland)

^c Division of Pneumology   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Biomarkers; Cardiopulmonary exercise testing; Endothelin; Peak oxygen consumption

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; COPEPTIN; PREPROENDOTHELIN 1; PROADRENOMEDULLIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHIECTASIS; CARDIOPULMONARY EXERCISE TEST; CHRONIC LUNG DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HEART FUNCTION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG CANCER; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; OXYGEN CONSUMPTION; OXYGENATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SARCOIDOSIS;

ADRENOMEDULLIN; ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; ENDOTHELIN-1; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; VITAL CAPACITY;

EID: 78649325087     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319038     Document Type: Article

References (43)

1. Ferrazza AM, Martolini D, Valli G, Palange P: Cardiopulmonary exercise testing in the functional and prognostic evaluation of pa-tients with pulmonary diseases. Respiration 2009; 77:3-17.
2. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, Gosselink R, O'Donnell DE, Puente-Maestu L, Schols AM, Singh S, Whipp BJ: Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007; 29: 185-209. (Pubitemid 46092015)
3. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-277.
4. 2 in patients with lung disease. Respir Med 2009; 103:1337-1345.
5. Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT: Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines, ed 2. Chest 2007; 132: 161S-177S. (Pubitemid 47502806)
6. Benzo R, Kelley GA, Recchi L, Hofman A, Sciurba F: Complications of lung resection and exercise capacity: a meta-analysis. Respir Med 2007; 101:1790-1797.
7. Benzo RP, Sciurba FC: Oxygen consump-tion, shuttle walking test and the evalua-tion of lung resection. Respiration 2010;80: 19-23.
8. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE: Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362:217-227.
9. Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Diaz H, Celli BR, Pinto-Plata VM: Effects of hyperinflation on the oxygen pulse as a marker of cardiac perfor-mance in COPD. Eur Respir J 2008; 32:1275-1282.
10. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Berg-mann A, Davies JE, Ng LL: Plasma N-termi-nal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midre-gional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarc-tion Peptide) study. J Am Coll Cardiol 2008; 51: 1857-1864.
11. von Haehling S, Jankowska EA, Morgentha-ler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papas-sotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD: Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting sur-vival in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1973-1980.
12. Moertl D, Berger R, Struck J, Gleiss A, Ham-mer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R: Comparison of midregional pro-atrial and B-type natriuret-ic peptides in chronic heart failure: influenc-ing factors, detection of left ventricular sys-tolic dysfunction, and prediction of death. J Am Coll Cardiol 2009; 53: 1783-1790.
13. Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, Davies J, Berg-mann A, Ng LL: Prognostic value of midre-gional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Pep-tide) study. J Am Coll Cardiol 2007; 49:1525-1532. (Pubitemid 46517963)
14. Khan SQ, Dhillon O, Struck J, Quinn P, Mor-genthaler NG, Squire IB, Davies JE, Berg-mann A, Ng LL: C-terminal pro-endothe-lin-1 offers additional prognostic infor-mation in patients after acute myocardial infarction: Leicester Acute Myocardial In-farction Peptide (LAMP) Study. Am Heart J 2007; 154:736-742.
15. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R: Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic pep-tide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008; 52: 266-272.
16. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Da-vies JE, Bergmann A, Ng LL: C-terminal pro-vasopressin (copeptin) as a novel and prog-nostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Pep-tide (LAMP) study. Circulation 2007; 115: 2103-2110.
17. Maeder MT, Brutsche MH, Christ A, Staub D, Noveanu M, Breidthardt T, Schaub N, Po-tocki M, Reichlin T, Morgenthaler NG, Berg-mann A, Mueller C: Midregional pro-A-type natriuretic peptide for the evaluation of ex-ercise intolerance. Int J Cardiol 2009, Dec 22. Epub ahead of print.
18. Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley LJ, Bur-nett JC, Jr: Cardiac secretion of adreno-medullin in human heart failure. J Clin In-vest 1996; 97: 2370-2376.
19. Pousset F, Masson F, Chavirovskaia O, Is-nard R, Carayon A, Golmard JL, Lechat P, Thomas D, Komajda M: Plasma adreno-medullin, a new independent predictor of prognosis in patients with chronic heart fail-ure. Eur Heart J 2000; 21:1009-1014.
20. Haynes WG, Strachan FE, Webb DJ: Endo-thelin ETA and ETB receptors cause vaso-constriction of human resistance and capac-itance vessels in vivo. Circulation 1995; 92: 357-363.
21. Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR Abman SH: Circu-lating immunoreactive endothelin-1 in chil-dren with pulmonary hypertension. Associ-ation with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993; 148: 519-522.
22. Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49.
23. Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, Davies JE, Ng LL: C-ter-minal provasopressin (copeptin) is associat-ed with left ventricular dysfunction, remod-eling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008; 14: 739-745.
24. Maeder MT, Brutsche MH, Staub D, Mor-genthaler NG, Bergmann A, Noveanu M, Laule K, Breidthardt T, Christ A, Klima T, Reichlin T, Potocki M, Mueller C: B-type na-triuretic peptide and C-terminal-pro-endo-thelin-1 for the prediction of severely im-paired peak oxygen consumption. J Intern Med 2009; 265: 604-615.
25. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL, Gibbons RJ, Antman EM, Al-pert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC: ACC/AHA 2002 guideline update for ex-ercise testing: summary article. A report of the American College of Cardiology/Ameri-can Heart Association Task Force on Prac-tice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40: 1531-1540. (Pubitemid 35192881)
26. Robbins M, Francis G, Pashkow FJ, Snader CE, Hoercher K Young JB, Lauer MS: Venti-latory and heart rate responses to exercise: better predictors of heart failure mortality than peak oxygen consumption. Circulation 1999; 100: 2411-2417.
27. Schmid A, Schilter D, Fengels I, Chhajed PN, Strobel W, Tamm M, Brutsche MH: Design and validation of an interpretative strategy for cardiopulmonary exercise tests. Respi-rology 2007; 12: 916-923.
28. Morgenthaler NG, Struck J, Thomas B, Berg-mann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic pep-tide in human plasma. Clin Chem 2004; 50: 234-236.
29. Morgenthaler NG, Struck J, Alonso C, Berg-mann A: Measurement of midregional pro-adrenomedullin in plasma with an immuno-luminometric assay. Clin Chem 2005; 51: 1823-1829.
30. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A: Immunolumino-metric assay for measurement of the C-ter-minal endothelin-1 precursor fragment in human plasma. Clin Chem 2006; 52:1144-1151.
31. Morgenthaler NG, Struck J, Alonso C, Berg-mann A: Assay for the measurement of co-peptin, a stable peptide derived from the pre-cursor of vasopressin. Clin Chem 2006; 52: 112-119.
32. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biomet-rics 1988; 44: 837-845.
33. Wieshammer S, Dreyhaupt J, Basler B, Mar-sovszky E: NT-proBNP for pulmonologists: not only a rule-out test for systolic heart fail-ure but also a global marker of heart disease. Respiration 2009; 77: 370-380.
34. Socrates T, Muller C: Natriuretic peptides find a new home in pulmonology. Respira-tion 2009; 77:368-369.
35. Kinugawa T, Kato M, Ogino K, Osaki S, Iga-wa O, Hisatome I, Shigemasa C: Plasma en-dothelin-1 levels and clinical correlates in patients with chronic heart failure. J Card Fail 2003; 9: 318-324.
36. Jorgensen K, Muller MF, Nel J, Upton RN, Houltz E, Ricksten SE: Reduced intrathorac-ic blood volume and left and right ventricu-lar dimensions in patients with severe em-physema: an MRI study. Chest 2007; 131: 1050-1057.
37. Holverda S, Rietema H, Westerhof N, Mar-cus JT, Gan CT, Postmus PE, Vonk-Noorde-graaf A: Stroke volume increase to exercise in chronic obstructive pulmonary disease is limited by increased pulmonary artery pres-sure. Heart 2009; 95: 137-141.
38. Vonk Noordegraaf A, Marcus JT, Roseboom B, Postmus PE, Faes TJ, de Vries PM: The ef-fect of right ventricular hypertrophy on left ventricular ejection fraction in pulmonary emphysema. Chest 1997; 112: 640-645.
39. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-585.
40. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM: Echocardiographic assess-ment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740.
41. Schols AM, Gosker HR: The pathophysiolo-gy of cachexia in chronic obstructive pulmo-nary disease. Curr Opin Support Palliat Care 2009; 3:282-287.
42. Yoshihara F, Ernst A, Morgenthaler NG, Horio T, Nakamura S, Nakahama H, Nakata H, Bergmann A, Kangawa K, Kawano Y: Midregional proadrenomedullin reflects cardiac dysfunction in haemodialysis pa-tients with cardiovascular disease. Nephrol Dial Transplant 2007; 22:2263-2268.
43. Wieshammer S, Dreyhaupt J, Basler B: A link between impaired lung function and in-creased cardiac stress. Respiration 2010; 79: 355-362.